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Neonatal sepsis or septicaemia is a
clinical syndrome characterized by sys-
temic signs of circulatory compromise
(e.g., poor peripheral perfusion, pallor,
hypotonia, poor responsiveness) caused by
invasion of the bloodstream by bacteria in
the first month of life. In the pre-antibiotic
era neonatal sepsis was usually fatal. Case
fatality rates in antibiotic treated infants
now range between 5% and 60% with the
highest rates reported from the lowest-
income countries [1]. The World Health
Organization (WHO) estimates that 1
million deaths per year (10% of all
under-five mortality) are due to neonatal
sepsis and that 42% of these deaths occur
in the first week of life [2]. There are wide
disparities in neonatal care between high-
and low-income countries. In high-income
countries the major concern is the increas-
ing numbers of extremely premature
infants with high nosocomial infection
rates due to multiresistant organisms in
intensive care units. Health facility infec-
tions are also a major problem in low-
income countries, but the more pressing
issues are the high proportion of home
deliveries in unclean environments predis-
posing to sepsis and ensuring that all
neonates have access to effective interven-
tions from health care providers in the first
days of life2. Indeed, new strategies that
can prevent, diagnose, and treat neonates
with sepsis are needed in both low- and
high-income settings.
Pathogenesis of Neonatal
Infections
Distal risk factors for neonatal sepsis
include poverty and poor environmental
conditions. Proximate factors include pro-
longed rupture of membranes, preterm
labour, maternal pyrexia, unhygienic in-
trapartum and postnatal care, low birth
weight, and prelacteal feeding of contam-
inated foods and fluids [3–5].
The bacteria that cause neonatal sepsis
are acquired shortly before, during, and
after delivery (Figure 1). They can be
obtained directly from mother’s blood,
skin, or vaginal tract before or during
delivery or from the environment during
and after delivery. Streptococcus agalactiae
(Group B streptococcus, GBS) is the most
common cause of neonatal sepsis in many
countries, though low rates are reported
from many low-income countries, espe-
cially those in south Asia.[6–8]; gram-
negative bacilli (Escherichia coli, Klebsiella
spp., Pseudomonas spp., Acinetobacter spp.)
and gram-positive cocci (such as Staphylo-
coccus aureus and Staphylococcus epidermidis)
are other important causes [6–8]. Howev-
er, there are many difficulties in interpret-
ing aetiological neonatal sepsis data,
because many studies report selected
populations of high-risk infants. Specimens
from infants in the first 24 hours of life are
also seriously under-represented, especially
those from low birth-weight babies and
babies born outside health facilities
[6,9–11]. Intrapartum antibiotic prophy-
laxis against S. agalactiae has also led to a
substantial change in the bacteria respon-
sible for early onset neonatal sepsis; gram-
negative bacilli and Staphylococcus spp.
predominate in countries implementing
these programs [12].
There are also many other important
neonatal infectious disease pathogens that
are not associated with the sepsis syndrome
including: Treponema pallidum, rubella virus,
herpes simplex virus, cytomegalovirus,
toxoplasmosis, Clostridium tetani, HIV, hep-
atitis B virus, and Bordetella pertussis (Figure 1)
[1,7,13]. These infectious pathogens cause
serious morbidities in young infants and
multifaceted disease syndromes including
congenital anomalies, developmental dis-
abilities, chronic liver disease, neonatal
tetanus, and apnoea. They are also impor-
tant causes of morbidity and mortality in
older age groups. However, only pathogens
that cause neonatal sepsis are discussed in
this paper.
Neonatal Immunity
Neonates have a functionally immature
immune system. They have extremely low
immunoglobulin (Ig) levels except for IgG
to specific maternal antigens transferred
passively across the placenta during the
last trimester of pregnancy [14,15]. T cell
function is relatively unimpaired but
complement activity is half that of healthy
adults. Neonates have a low neutrophil
storage pool, and their existing neutrophils
have impaired capacity to migrate from
the blood to sites of infection [16].
The basal expression of Toll-like recep-
tors (TLRs, receptors that detect the
presence of microbes) is similar in the
neonate and adult [17]. However, innate
immune responses of neonatal mononu-
clear cells are characterised by markedly
reduced release of the proinflammatory
Th1-polarizing cytokines tumour necrosis
factor-alpha (TNF-a) and interferon-gam-
ma (IFN-c) with relative preservation of
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anti-inflammatory Th2-polarizing cyto-
kines such as interleukin 6 (IL6) [18].
These findings may reflect in utero require-
ments, including the avoidance of harmful
inflammatory immune reactions [19].
These immunological problems are
reflected in the clinical presentation of
neonatal sepsis. Neonates have a rapid and
fulminant progression of septicaemic dis-
ease, nonspecific clinical signs of infection,
and difficult-to-interpret laboratory results
including haematological and immunolog-
ical biomarkers of infection and inflam-
mation. Low birth-weight (preterm and
small for gestational age) infants have even
poorer functional immunity, and are
especially at risk of sepsis [19].
However, neonates do have well-func-
tioning cationic membrane-active antimi-
crobial proteins and peptides (APPs) which
have microbicidal properties [15,19].
These APPs can be found in the vernix
caseosa covering the skin at birth, and in
the neonatal gastrointestinal and respira-
tory tracts.
Advances in Prevention
Before Delivery
Many older studies have demonstrated
that improving maternal health and nutri-
tion before delivery is directly associated
with improved neonatal health outcomes
[3]. Randomised controlled trials (RCTs)
of maternal protein-calorie and multiple
micronutrient and supplementation have
demonstrated significant improvements in
rates of prematurity and birth weight and
variable impact on mortality; but no
studies have examined their impact on
rates of neonatal sepsis [20,21].
Maternal immunisation is an important
method of providing neonates with appro-
priate antibodies as soon as they are born
[22]. This approach is less sensitive to
obstacles in accessing the health care
system than are other approaches, and
examples of successful interventions in-
clude maternal tetanus toxoid and influ-
enza immunisations [23,24]. Studies of
maternal immunisation with S. agalactiae
type III conjugate vaccine have demon-
strated excellent placental transfer and
persistence of protective levels in 2-
month-old infants [22]. Phase I and II
trials of other serotypes in nonpregnant
women have also demonstrated safety and
immunogenicity. A recent modelling study
estimated that vaccination with S. agalactiae
vaccine would prevent 4% of US preterm
births and 60%–70% of neonatal S.
agalactiae infections [25]. Encouraging re-
sults are also emerging from studies of
maternal immunisation with pneumococ-
cal polysaccharide and conjugate vaccines
[22,26]. The vaccines all have excellent
safety profiles. However, barriers to ma-
ternal immunisation include: liability is-
sues for vaccine manufacturers in devel-
oped countries; education of the public
and health care providers regarding the
benefits of maternal immunisation; and
poor ascertainment of data from low-
income countries [22].
During Labour and Delivery
There is strong evidence that clean
delivery practices and handwashing during
delivery reduces rates of neonatal sepsis in
both home and health facility settings
[27–29]. Interventions to improve hand-
washing rates have been remarkably
successful in research settings [30,31].
The reasons for lack of successful scale-
up of handwashing interventions into
policy, programs, and behaviour change
are less clear [32].
New studies from Malawi and Nepal
indicate that maternal antisepsis interven-
tions such as vaginal chlorhexidine during
labour may have a significant impact on
rates of neonatal mortality and sepsis in
developing countries [33]. However, other
studies from high-income countries have
demonstrated little effect on rates of HIV
or neonatal infections [34].
Intrapartum antibiotic prophylaxis has
been highly effective in reducing both
early-onset neonatal bacterial and mater-
nal sepsis in developed countries [35].
Chemoprophylaxis in the US has halved
the incidence of early-onset neonatal
bacterial sepsis caused by S. agalactiae from
1.7 per 1,000 live births in 1993 to 0.6 per
1,000 in 1998 [36]. Clear protocols are in
place in high-income countries for the
management of women with risk factors
for neonatal sepsis [37]. Risk factors for
early-onset neonatal bacterial sepsis in
low-income settings are probably similar
to resource-rich settings, but have not
been evaluated in the context of high rates
of maternal undernutrition, anaemia,
HIV, and malaria.
After Delivery
There is also strong evidence that
handwashing by health care providers
after delivery can reduce neonatal sepsis
and infection rates, especially in hospitals
[27,28]. There is less evidence for the
importance of rigorous handwashing and
use of antiseptics in mothers of their own
infants.
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In high-income settings, studies have
not shown an advantage of antibiotics or
antiseptics over simply keeping the umbil-
ical cord clean [2]. However, umbilical
stump chlorhexidine cleansing has recently
been shown to substantially reduce neo-
natal deaths in Nepal [38]. Other studies
investigating the effects of chlorhexidine
on prevention of omphalitis are currently
underway in several countries [39].
There is emerging evidence that neo-
natal skin antisepsis preparations such as
sunflower seed oil provides cheap, safe,
and effective protection against nosocomi-
al infections in hospitalized preterm neo-
nates and infants in studies in south Asia.
Application of chlorhexidine to neonatal
skin has also been shown to be effective in
reducing neonatal sepsis in studies from
south Asia [39,40].
Neonatal immunisation has long been
considered an important method of re-
ducing neonatal infections. However, re-
sponse varies according to the antigen
[15]. BCG, polio, and hepatitis B vaccines
are highly immunogenic when given at
birth [41]. However, maternal antibodies
interfere with a neonate’s response to
measles vaccine when administered under
six months. Protein antigen vaccines (e.g.,
pertussis and tetanus toxoid) given at birth
have been shown to produce poor re-
sponses compared to the same antigen
given at two months of age and are
associated with later tolerance [41]. Stud-
ies also indicate that S. agalactiae and
Streptococcus pneumoniae vaccines are both
likely to be ineffective when given in the
neonatal period [15].
Breastmilk contains secretory IgA, lyso-
zymes, white blood cells, and lactoferrin
and has been shown to encourage the
growth of healthy lactobacilli and reduce
the growth of E. coli and other gram-
negative pathogenic bacteria [15]. RCTs
that focused on increasing early initiation
and exclusive breastfeeding rates demon-
strated significant reductions in diarrhoea
and acute respiratory infections in neo-
nates and older infants in India [42].
Other observational studies have demon-
strated impact on infection specific mor-
tality rates and all-cause mortality during
the neonatal period [43–45].
Neonatal micronutrient supplementa-
tion trials have focused on vitamin A
supplementation. Older studies have
shown significant reductions in respiratory
disease in low birth-weight infants after the
administration of parenteral vitamin A
[46]. More recently, trials of newborn
vitamin A supplementation have shown
encouraging reductions in neonatal mor-
tality, and more trials are underway [47].
In high-income countries, clinical trials of
immune stimulants such as granulocyte/
monocyte colony stimulating factor (GM-
CSF) to enhance the quantity and quality of
neonatal neutrophils and monocytes appear
promising but have not yet shown a
significant clinical benefit [15]. The evalu-
ation of recombinant APPs as adjunctive
therapy for neonatal infection are still under
evaluation. The impact of TLR agonists to
improve defences against microorganisms
are also being evaluated [15].
Advances in Diagnosis
Neonatal clinical sepsis syndrome iden-
tification is difficult as the clinical signs of
Figure 1. Pathogenesis of congenital and neonatal infections.
doi:10.1371/journal.pmed.1000213.g001
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neonatal septicaemia can be very similar
to those of other life-threatening diseases
such as necrotising enterocolitis, hyaline
membrane disease, and perinatal asphyxia
[48,49]. However, recent studies in mid-
dle- and low-income countries have pro-
vided seven danger signs which can be
used to identify infants with very severe
disease including neonatal sepsis (Table 1)
[49]. These signs provide high sensitivity
and moderate specificity for detecting
serious illness in newborns in low-resource
settings and have now been incorporated
into the new neonatal WHO Integrated
Management of Childhood Illness (n-
IMCI) guidelines.
Identification of neonatal sepsis before
delivery also remains challenging. A com-
bination of maternal risk factors and
clinical signs and symptoms is currently
used [50]. However, peripartum proteo-
mic analysis of the amniotic fluid is now
offering the opportunity for early and
accurate diagnosis of early-onset neonatal
sepsis in the select population of women
undergoing amniocentesis in high-risk
pregnancies [51,52].
Confirmation of pathogenic organisms
allows targeted antibiotic therapy. How-
ever, identification of pathogenic organ-
isms in neonates with sepsis syndrome is
fraught with difficulties. Bacterial load
may be low due to mothers receiving
antepartum or intrapartum antibiotics and
because only small amounts of blood can
often be taken from newborns [53].
Contamination rates may also be very
high due to the technical difficulties of
sterile venipuncture in small babies. There
may also be misinterpretation of the role
of coagulase-negative staphylococci (e.g.,
S. epidermidis), as these organisms are both
normal skin flora and pathogenic organ-
isms in preterms and infants with indwell-
ing blood vessel catheters [54].
Automated blood culture systems have
long been considered the gold standard for
microbiological diagnosis. However, de-
spite improvements in growth media and
instrumentation, results of blood culture
can be delayed by up to 48 hours [53,55].
The condition of a neonate with true sepsis
can deteriorate quickly, thus the most
common approach is to initiate empiric
broad-spectrum antibiotic therapy in all
young infants with suspected bacterial
infection [49]. A negative blood culture
after 48 hours may allow cessation of
antibiotic therapy in a well infant. While
appropriately cautious, this practice leads
to antibiotic exposure in a large number of
newborns for whom antibiotic treatment
may be unnecessary since blood cultures
are positive in only 5%–10% of suspected
sepsis cases, even at highly resourced
facilities [56].
Antigen detection techniques allow rap-
id detection and identification of microor-
ganisms without culturing. The most
commonly used commercially available
test is the latex agglutination assay, which
is based on specific agglutination by
bacterial cell wall antigens of antibody-
coated latex particles. However, these tests
can only detect specific organisms such as
S. agalactiae and are associated with high
false positive and negative rates [57]. New
urinary antigen tests for pneumococcus
are more encouraging but are also associ-
ated with false positives from pneumococ-
cal carriage [58].
The polymerase chain reaction (PCR)
has been widely used in biomedical re-
search laboratories for pathogen identifica-
tion in neonatal sepsis and in some clinical
hospital laboratories. The high sensitivity of
PCR allows detection of bacterial DNA
even when concentrations are low [57].
Conventional assays are being replaced by
a newer ‘‘real-time’’ system, which is faster
and associated with lower contamination
rates because amplification and detection
occur simultaneously in a closed system
[59]. The real-time PCR is based on the
measurement of a fluorescent signal gener-
ated during each amplification cycle. It
produces quantitative results within 30
minutes and calculates bacterial load.
Broad-range real-time PCR uses a single
primer to detect the universal bacterial
genome (16S RNA or 23S RNA) which is a
conserved ribosomal genome sequence
across all bacterial genera [60]. Broad-
range real-time PCR can be used to
distinguish bacterial septicaemic disease
from other causes of neonatal illness such
as asphyxia or complications of prematuri-
ty. However, it has been used with varying
success in the analysis of whole blood for
neonatal sepsis; specificity is generally high
but sensitivity can be as low as 40% [60,61].
In contrast, multiplex PCR involves the
parallel amplification of different targets
but is focused only on specific pathogens,
and false negatives can occur if the
aetiologic agent of interest is not included
in the database [62]. Real-time PCR is now
often used to screen for microbial load,
followed by sequence-based targeting and
identification of PCR amplicons (pyrose-
quencing) [62]. This process can detect
very small copy numbers of specific nucleic
acid sequences. There is also a new
commercially available multiplex pyrose-
quencing PCR assay which can identify up
to 40 different bacterial and fungal patho-
gens directly from whole blood [63]. Real-
time PCR and pyrosequencing of the
universal 23S rRNA gene has also recently
been used successfully in neonatal blood
culture samples [64]. Further tests on
neonatal whole blood have been planned
by a number of different research groups.
The biggest problem with real time
PCR testing is that the specimen must be
collected with a sterile venipuncture,
which may be difficult in young neonates.
Neonatal capillary heel prick specimens
are easier to collect but highly contami-
nated by skin flora. There is also high
potential for contamination of enrichment
media, reagents, or the sample during
collection and processing [61] Other
problems include low sensitivity due to
competition from human DNA in whole
blood, especially if white cell counts are
high. Also, bacterial organisms require
lysis before their DNA can be available for
analysis, and gram-positive organisms are
difficult to lyse because of their resilient
cell wall [61]. Real-time PCR technologies
are also expensive and currently can be
used only by highly trained staff.
Important haematological tests include
microscopic examination of the blood for
white cells (total leucocyte count, differen-
tial, neutrophil count, and immature
neutrophil to total neutrophil ratio). Ad-
vantages are that these specimens do not
require sterility and a heel prick specimen
can be used. However many of these
indices are falsely low in a septic neonate.
Biological biomarkers are human blood
components that increase in response to
infection. The most commonly used acute
phase reactant is the C-reactive protein
(CRP). However, the CRP takes 12–
24 hours to increase to measurable levels;
its half life is very long and it takes 5–7 days
to normalize after eradication of the
infectious agent. Cytokines such as IL6,
IL8, TNF-a, and procalcitonin have also
been extensively studied [65,66]. Cytokines
rise quickly after infection even in neonates,
and are more sensitive to low concentra-
Table 1. Clinical symptoms and signs
of severe neonatal illness including
sepsis.
History of difficulty feeding
History of convulsions
Movement only when stimulated
Respiratory rate $60 breaths per minute
Severe chest indrawing
Axillary temperature $37.5uC
Axillary temperature ,35.5uC
From [49].
doi:10.1371/journal.pmed.1000213.t001
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tions of pathogens than CRP [66]. How-
ever, cord and postnatal blood cytokine
concentrations can be depressed in the
presence of pregnancy-induced hyperten-
sion and can rise after induced vaginal or
urgent cesarean delivery, delivery room
intubation, muscular damage, and inflam-
mation from other causes [57]. Simulta-
neous measurement of multiple biomarkers
may improve both sensitivity and specificity
[66,67]. However, biomarker assays are
likely to be less acceptable to physicians
who often place higher value on tests that
confirm biological agents and allow target-
ing of antibiotic therapy [57].
Microtechnologies, especially microflui-
dics, have provided the greatest recent
contribution to the diagnosis of neonatal
sepsis. Microfluidics is the study of the
behaviour, precise control, and manipula-
tion of fluids geometrically constrained to
submillimetre (nanolitre or picolitre) chan-
nels [68]. Microfluidic technology uses the
unique proprieties of continuous flow
micro-volume channels: viscosity, surface
tension, energy dissipation, and fluidic
resistance, and also includes micro pneu-
matic pump and valve systems. One
specific application of microfluidics is
bacterial DNA protein microarray hybrid-
ization [69]. In this test, DNA probes
specific to selected targets are spotted on a
glass or silicon slide in a known order.
Target DNA fragments are labelled with a
reporter molecule, combined into a single
hybrid, and measured using fluorescent
signals [62,68]. This technique has been
used in the identification of the specific
sepsis pathogen in bacterial meningitis,
acute viral respiratory tract infections, and
neonatal sepsis, and also in the detection
of their antimicrobial resistance and viru-
lence genes in research settings [63].
Microfluidic technology has also al-
lowed sample preparation and a number
of different assays to be combined in small,
disposable, single-use diagnostic cartridges
or cards that have been called a ‘‘lab on-a-
chip’’ or LOC (Figure 2) [68]. Some
LOCs have combined sample preparation,
biomarkers, real-time PCR, and DNA
microarrays to provide information about
indices of inflammation, pathogen identi-
fication, and antimicrobial susceptibility
patterns at the point of care [68,70].
LOCs have been reported to perform
assays at sensitivity, specificity, and repro-
ducibility levels similar to those of central
laboratory analysers, but yet require little
user input other than the insertion of the
sample. Single drops of blood, faeces, and
saliva have all been tested with encourag-
ing results. LOCs are currently being
evaluated for use in sepsis, endocarditis,
HIV, tuberculosis, severe acute respiratory
syndrome (SARS), and pneumonia [68].
However, they are not yet in clinical use
nor licensed by regulatory authorities.
Advances in Treatment
As neonatal sepsis can be rapidly fatal if
left untreated, highly effective antibiotic
therapy must be used and delays in the
provision of care must be minimised.
Figure 2. Example of ‘‘lab on a chip’’ point-of-care device.
doi:10.1371/journal.pmed.1000213.g002
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Treatment must be effective against the
causative pathogen, safe for the newborn,
and feasible to deliver reliably in the
hospital or community setting.
Parenteral (intravenous or intramuscu-
lar) regimens for neonatal sepsis currently
recommended by national paediatric as-
sociations are a combination of penicillin/
ampicillin and gentamicin, or third-gener-
ation cephalosporins (e.g., ceftriaxone or
cefotaxime) for 10–14 days. These antibi-
otics are safe and retain efficacy when
administered at extended intervals (e.g.,
twice daily or daily dosing) [56]. These
regimens are very effective against Strepto-
coccus spp., but Staphylococcus spp. can be
highly resistant [71]. Gram-negative anti-
microbial susceptibility to ampicillin and
gentamicin can also be poor, especially for
Klebsiella spp. [8,71]. Emerging E. coli
resistance to ampicillin, gentamicin, and
third-generation cephalosporins in hospi-
tal nurseries in both developed and
developing countries is also causing in-
creasing concern [8]. The potential for
significant life-threatening toxicity among
neonates associated with chloramphenicol
makes it the least preferred empiric
parenteral therapy [56].
Oral antibiotic therapy must be consid-
ered in settings where referral is not
possible and there are no health care
providers trained to give parenteral anti-
biotics [72]. The incremental benefit of
injectable over oral antibiotics is not
known, and oral antibiotic therapy is
better than no antibiotic therapy at all. A
series of trials are currently evaluating the
impact of home and clinic-based short
course (7 days) intramuscular and oral
antibiotic therapy for neonatal sepsis in
low-income countries [72]. Most data are
available on the effect of oral cotrimox-
azole in community-based treatment of
serious neonatal bacterial infections from
Nepal and India. However, there are
concerns about high resistance rates, and
side effects such as neonatal jaundice have
been reported [71]. Oral amoxicillin is
highly efficacious against Streptococcus spp.
and some gram-negative bacilli and has an
excellent safety record. However, it has no
anti-Staphylococcus coverage and resistance
is emerging in gram-negative bacilli such
as E. coli. New, better-absorbed oral
antibiotics are also being considered. The
new second-generation cephalosporins
(e.g., cefadroxil and cefuroxime) have an
excellent safety profile, a spectrum of
activity similar to cotrimoxazole, and
may be more effective given the high
resistance of neonatal pathogens to cotri-
moxazole. Ciprofloxacin also is increas-
ingly accepted as safe in neonates and
warrants further investigation for treat-
ment of infections in newborns. However,
the current cost of these agents and
potential for exacerbating antimicrobial
resistance may limit widespread use in
developing countries [72].
Poor maternal-neonatal health systems,
low levels of care-seeking, and lack of
access to sick newborns during the first
day of life, when mortality risks are
highest, are also important concerns
Table 2. Effective current measures and new approaches to prevent, diagnose, and treat neonatal sepsis.
Category Measure Item
Prevention Current measures Improved maternal health and nutrition
Clean delivery practices and handwashing
Risk-based intrapartum antibiotic prophylaxis
Hand washing from health care providers
Promotion of early initiation of exclusive breastfeeding
New approaches Maternal S. agalactiae and S. pneumoniae immunisation
Maternal vaginal chlorhexidine other antisepsis preparations
Neonatal protective and antisepsis skin preparations
Neonatal vitamin A supplementation
Recombinant active antimicrobial proteins
Toll like receptor agonists
Diagnosis Current measures Blood culture
Antigen detection
Blood neutrophil count and differential
C-reactive protein
New approaches Proteomic amniotic fluid analysis
Improved clinical syndrome identification
Real-time polymerase chain reaction
Interleukin inflammatory indices
Microfluidic microtechnologies
‘‘Lab on a chip’’ point of care devices
Treatment Current measures Parenteral antibiotics (penicillin/amoxycillin and gentamicin or third generation cephalosporins)
for 10–14 d
New approaches Shorter courses of antibiotic therapy
Better-absorbed oral antibiotics especially second generation cephalosporins and ciprofloxacin
Programs to increase the access of neonates in remote areas to health care providers in the first
days of life
doi:10.1371/journal.pmed.1000213.t002
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[73]. Recent studies have shown that
community health workers can deliver
antibiotic treatment to neonates with very
severe infections at home safely and
acceptably when hospitalization is not
feasible [74]. Trials are currently evalu-
ating the effectiveness, quality of care,
and coverage of these community health
worker programmes in Asia and Africa
[73]. Barriers to large-scale implementa-
tion include high cost, poor staff training
and retention, and difficulties with refer-
ral (e.g., lack of ambulances and poor
institutional links).
Summary and Next Steps
Newborn sepsis is a major cause of child
mortality across the world. Industrialized
countries have made remarkable progress
in reducing newborn sepsis and sepsis-
related mortality by providing access to
hygienic skilled delivery for all women,
risk-based intrapartum antibiotic prophy-
laxis, and high-quality intensive care for
newborns that need it. Although resource
constraints preclude whole-scale adoption
of these strategies in developing countries,
there are a number of low-cost proven
interventions and promising approaches
that have the potential to significantly
reduce the burden of neonatal sepsis
worldwide (Table 2).
However, practicability of implement-
ing these new advances must be consid-
ered. Skilled attendance at delivery is
increasing in low- and middle-income
countries. Thus, intrapartum approaches
such as risk-based antibiotic prophylaxis
and improved hand washing during deliv-
ery are likely to be both cost-effective and
feasible in these countries. More challeng-
es face the implementation of diagnostic
technologies. It may take many years for
technologies such as the ‘‘lab-on-a-chip’’
to be sufficiently robust and affordable for
scale-up to low-income countries. Home-
based antibiotic treatment of neonatal
sepsis also faces major obstacles to large-
scale implementation. Concerns such as
‘‘one law for the rich and another for the
poor’’ have already been raised. A careful
assessment of the risks and benefits of new
technologies and interventions is clearly
needed. In low-income settings there are
also difficulties with care-seeking for neo-
natal illnesses, and home visiting programs
are needed to identify sick newborns early
in life. Neonatal sepsis is also one of the
most rapidly fulminating clinical diseases,
and many practitioners, including experi-
enced neonatologists, administer parenter-
al antibiotics rather than wait for the
results of any diagnostic tests. These
practitioners rightly consider that the
individual patient’s health is more impor-
tant than the potential risks of emerging
antibiotic resistance.
Thus, front-line health workers and
families must be partners in all research
and evaluation planning. Detailed assess-
ment of end-user attitudes and preferences
using formative and qualitative research
methods must be included in the develop-
ment of programs to reduce morbidity and
mortality from neonatal sepsis. Finally,
advocacy for equitable resource allocation
across and within countries must be a
priority and modelling techniques to assess
public health impact of neonatal sepsis
interventions must be developed and used
more widely.
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